Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Cohen

Showing results (361-370 of 403) with videos related to

Pageof 41
Sort By:
The New England Journal of Medicine|December 14, 2016
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCIC Michael Gibson, Roxana Mehran, Christoph Bode, et al.
Thrombosis and Haemostasis|March 17, 2017
Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes statusMark R Thomas, Dominick J Angiolillo, Marc P Bonaca, et al.
European Journal of Psychotraumatology|February 3, 2025
International study of the perceived stress and psychological impact of the 7 October attacks on Holocaust survivorsBruno Halioua, Patrick Bantman, Rachel Rimmer, et al.
Journal of the American College of Cardiology|March 12, 2016
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 TrialRobert F Storey, Dominick J Angiolillo, Marc P Bonaca, et al.
American Heart Journal|July 18, 2018
Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trialGerald Chi, Mathieu Kerneis, Arzu Kalayci, et al.
Journal of Thrombosis and Thrombolysis|June 27, 2018
Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary interventionGerald Chi, Megan K Yee, Arzu Kalayci, et al.
International Journal of Particle Therapy|February 2, 2026
The Use of Protons in the Management of Recurrent, Previously Irradiated Adenoid Cystic CarcinomaIrini Yacoub, Achraf Shamseddine, Daniel Kallini, et al.
JAMA|July 9, 2004
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overviewJohn L Petersen, Kenneth W Mahaffey, Vic Hasselblad, et al.
American Heart Journal|December 13, 2006
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trialHarvey D White, Neal S Kleiman, Kenneth W Mahaffey, et al.
The American Journal of Cardiology|September 10, 2013
A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial)Jean-Philippe Collet, Kurt Huber, Marc Cohen, et al.
Pageof 41

Showing results (361-370 of 403) with videos related to

Sort By:
Pageof 41
The New England Journal of Medicine|December 14, 2016
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCIC Michael Gibson, Roxana Mehran, Christoph Bode, et al.
Thrombosis and Haemostasis|March 17, 2017
Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes statusMark R Thomas, Dominick J Angiolillo, Marc P Bonaca, et al.
European Journal of Psychotraumatology|February 3, 2025
International study of the perceived stress and psychological impact of the 7 October attacks on Holocaust survivorsBruno Halioua, Patrick Bantman, Rachel Rimmer, et al.
Journal of the American College of Cardiology|March 12, 2016
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 TrialRobert F Storey, Dominick J Angiolillo, Marc P Bonaca, et al.
American Heart Journal|July 18, 2018
Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trialGerald Chi, Mathieu Kerneis, Arzu Kalayci, et al.
Journal of Thrombosis and Thrombolysis|June 27, 2018
Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary interventionGerald Chi, Megan K Yee, Arzu Kalayci, et al.
International Journal of Particle Therapy|February 2, 2026
The Use of Protons in the Management of Recurrent, Previously Irradiated Adenoid Cystic CarcinomaIrini Yacoub, Achraf Shamseddine, Daniel Kallini, et al.
JAMA|July 9, 2004
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overviewJohn L Petersen, Kenneth W Mahaffey, Vic Hasselblad, et al.
American Heart Journal|December 13, 2006
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trialHarvey D White, Neal S Kleiman, Kenneth W Mahaffey, et al.
The American Journal of Cardiology|September 10, 2013
A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial)Jean-Philippe Collet, Kurt Huber, Marc Cohen, et al.
Pageof 41